eISSN: 2354-0265
ISSN: 2353-6942
Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO
Bieżący numer Archiwum Online first O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
Poleć ten artykuł:
Udostępnij:
Artykuł przeglądowy

LECZENIE TRĄDZIKU POSPOLITEGO, CZYLI WSZYSTKO CO POWINNIŚMY WIEDZIEĆ O IZOTRETYNOINIE

Aneta Jerzak
1
,
Katarzyna Jakubowska
1
,
Aleksandra Janocha
2
,
Paweł Ziemba
2

  1. Ludwik Rydygier Specialist Hospital in Kraków, Poland
  2. Independent Public Healthcare Center number 1 in Rzeszów, Poland
Helth Prob Civil.
Data publikacji online: 2024/09/05
Plik artykułu:
- Jerzak et al.pdf  [0.77 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Bettoli V, Guerra-Tapia A, Herane MI, Piquero-Martín J. Challenges and solutions in oral isotretinoin in acne: reflections on 35 years of experience. Clin Cosmet Investig Dermatol. 2019; 12: 943-951. https://doi.org/10.2147/ccid.s234231 
2. Rocha M, Barnes F, Calderón J, Fierro-Arias L, Gomez CEM, Munoz C et al. Acne treatment challenges - Recommendations of Latin American expert consensus. An Bras Dermatol. 2024; 99(3): 414-424. https://doi.org/10.1016/j.abd.2023.09.001
3. Santer M, Burden-Teh E, Ravenscroft J. Managing acne vulgaris: an update. Drug Ther Bull. 2023; 62(1): 6-10. https://doi.org/10.1136/dtb.2023.000051
4. Melnik BC. Acne transcriptomics: fundamentals of acne pathogenesis and isotretinoin treatment. Cells. 2023; 12(22): 2600. https://doi.org/10.3390/cells12222600
5. Bellomo R, Brunner M, Tadjally E. New formulations of isotretinoin for acne treatment: expanded options and clinical implications. J Clin Aesthet Dermatol. 2021; 14(12Suppl.1): 18-23.
6. Oge' LK, Broussard A, Marshall MD. Acne vulgaris: diagnosis and treatment. Am Fam Physician. 2019; 100(8): 475-484.
7. Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020; 10(1): 5754. https://doi.org/10.1038/s41598-020-62715-3 
8. Wilcock J, Kuznetsov L, Ravenscroft J, Rafiq MI, Healy E. New NICE guidance on acne vulgaris: implications for first-line management in primary care. Br J Gen Pract. 2021; 71(713): 568-570. https://doi.org/ 10.3399/bjgp21X717977 
9. Chandrasekaran S, De Sousa JFM, Paghdar S, Khan TM, Patel NP, Tsouklidis N. Is isotretinoin in acne patients a psychological boon or a bane: a systematic review. Cureus. 2021; 13(8): e16834. https://doi.org/10.7759/cureus.16834 
10. Pile HD, Sadiq NM. Isotretinoin. [Internet]. StatPearls Publishing; 2024 [access 2023 May 1] Available from: https://www.ncbi.nlm.nih.gov/books/NBK525949/
11. Agamia NF, El Mulla KF, Alsayed NM, Ghazala RM, El Maksoud REA, Abdelmeniem IM et al. Isotretinoin treatment upregulates the expression of p53 in the skin and sebaceous glands of patients with acne vulgaris. Arch Dermatol Res. 2023; 315(5): 1355-1365. https://doi.org/10.1007/s00403-022-02508-y 
12. Mobacken H. [Treatment with low-dose isotretinoin is effective for patients with moderate inflammatory acne]. Lakartidningen. 2021; 118: 21117 (in Swedish).
13. Bagatin E, Costa CS, Rocha MADD, Picosse FR, Kamamoto CSL, Pirmez R, et al. Consensus on the use of oral isotretinoin in dermatology – Brazilian Society of Dermatology. An Bras Dermatol. 2020; 95(Suppl 1): 19-38. https://doi.org/10.1016/j.abd.2020.09.001 
14. Kapała J, Lewandowska J, Placek W, Owczarczyk-Saczonek A. Adverse events in isotretinoin therapy: a single-arm meta-analysis. Int J Environ Res Public Health. 2022; 19(11): 6463. https://doi.org/10.3390/ijerph19116463
15. İslamoğlu ZGK, Altınyazar HC. Effects of isotretinoin on the hair cycle. J Cosmet Dermatol. 2019; 18(2): 647-651. https://doi.org/10.1111/jocd.12800
16. Tran PT, Evron E, Goh C. Characteristics of patients with hair loss after isotretinoin treatment: a retrospective review study. Int J Trichology. 2022; 14(4): 125-127. https://doi.org/10.4103/ijt.ijt_80_20 
17. Greywal T, Zaenglein AL, Baldwin HE, Bhatia N, Chernoff KA, Del Rosso JQ, et al. Evidence-based recommendations for the management of acne fulminans and its variants. Journal of the American Academy of Dermatology. 2017; 77(1): 109-117. https://doi.org/10.1016/j.jaad.2016.11.028
18. Fakih A, Goens J, Grozdev I, Dangoisse C, Richert B. Acne fulminans induced by a low dose isotretinoin: case report and review of the literature. Dermatology Online Journal. 2020; 26(12): 13030/qt14h2419w. https://doi.org/10.5070/D32612051358
19. Lamberg O, Strome A, Jones F, Mleczek J, Jarocki A, Troost JP, et al. Ocular side effects of systemic isotretinoin – a systematic review and summary of case reports. J Dermatolog Treat. 2023; 34(1): 2213364. https://doi.org/10.1080/09546634.2023.2213364
20. Zakrzewska A, Wiącek MP, Słuczanowska-Głąbowska S, Safranow K, Machalińska A. The effect of oral isotretinoin therapy on meibomian gland characteristics in patients with acne vulgaris. Ophthalmol Ther. 2023; 12(4): 2187-2197. https://doi.org/10.1007/s40123-023-00737-6 
21. AlMasoudi RM, Bahaj RK, Kokandi AA. Patients' awareness of the ocular side effects of isotretinoin therapy: a study from Saudi Arabia. Cureus. 2022; 14(4): e24628. https://doi.org/10.7759/cureus.24628 
22. Tasli H, Yurekli A, Gokgoz MC, Karakoc O. Effects of oral isotretinoin therapy on the nasal cavities. Braz J Otorhinolaryngol. 2020; 86(1): 99-104. https://doi.org/10.1016/j.bjorl.2018.10.004 
23. Algamdi BN, ALdahlan HW, ALALhareth H, Alghamdi R, Alkhouzaie MT, ALahmari N, et al. Evaluating depression among acne vulgaris patients treated with isotretinoin. Cureus. 2020; 12(12): e12126. https://doi.org/10.7759/cureus.12126 
24. AlGhofaili FA. Isotretinoin use and risk of depression in acne vulgaris patients in Riyadh, Saudi Arabia. Cureus. 2021; 13(3): e13680. https://doi.org/10.7759/cureus.13680 
25. Droitcourt C, Nowak E, Rault C, Happe A, Le Nautout B, Kerbrat S, et al. Risk of suicide attempt associated with isotretinoin: a nationwide cohort and nested case-time-control study. Int J Epidemiol. 2019; 48(5): 1623-1635. https://doi.org/10.1093/ije/dyz093
26. Demir EY, Köse ÖK. Effects of oral isotretinoin treatment for acne vulgaris patients on anger responses and the relationship with temperament. Rev Assoc Med Bras. 2023; 70(1): e20230592. https://doi.org/10.1590/1806-9282.20230592 
27. Mülkoğlu C, Karaosmanoğlu N. Effect of oral isotretinoin on muscle strength in patients with acne vulgaris: a prospective controlled study. BMC Pharmacol Toxicol. 2021; 22(1): 17. https://doi.org/10.1186/s40360-021-00483-0
28. Özkoca D, Caf N, Alacagöz Yılmaz NN, Uzunçakmak TK, Özdil A, Atsü AN. Skeletal side effects of systemic isotretinoin treatment: do they depend on age, gender, treatment duration, daily dose and isotretinoin-naiveness?. Dermatol Pract Concept. 2023; 13(2): e2023121. https://doi.org/10.5826/dpc.1302a121
29. Paichitrojjana A, Paichitrojjana A. Oral isotretinoin and its uses in dermatology: a review. Drug Des Devel Ther. 2023; 17: 2573-2591. https://doi.org/10.2147/DDDT.S427530
30. Alajaji A, Alrawaf FA, Alosayli SI, Alqifari HN, Alhabdan BM, Alnasser MA. Laboratory abnormalities in acne patients treated with oral isotretinoin: a retrospective epidemiological study. Cureus. 2021; 13(10): e19031. https://doi.org/10.7759/cureus.19031 
31. Barbieri JS, Shin DB, Wang S, Margolis DJ, Takeshita J. The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time. J Am Acad Dermatol. 2020; 82(1): 72-79. https://doi.org/10.1016/j.jaad.2019.06.025
Copyright: © 2024 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

© 2024 Termedia Sp. z o.o.
Developed by Bentus.